No Independent Influence of Statins on the Chronic Obstructive Pulmonary Disease Exacerbation Rate: A Cohort Observation Study Over 10 Years

References

• Weingärtner O, Lütjohann D, Böhm M, Laufs U. Cholesterinhomöostase und kardiovaskuläres Risiko [Cholesterol homeostasis and cardiovascular risk]. Dtsch Med Wochenschr. 2011;136(1–2):34–38. doi:10.1055/s-0030-1269438
   PubMed Web of Science ®Google Scholar
• Cherepanov D, Bentley TGK, Hsiao W, et al. Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review. Curr Med Res Opin. 2018;34(3):459–473. doi:10.1080/03007995.2017.1401529
   PubMed Web of Science ®Google Scholar
• Shen H, Rui L, Yan R, et al. Adjunctive therapy with statins in schizophrenia patients: a meta-analysis and implications. Psychiatry Res. 2018;262:84–93. doi:10.1016/j.psychres.2018.02.018
   PubMed Web of Science ®Google Scholar
• Noseda G, Darioli R, Keller U, et al. Prüfung der Wirksamkeit und Verträglichkeit von Atorvastatin bei Hyperlipidämie unter Praxisbedingungen (SWITCH-Studie) [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)]. Schweiz Med Wochenschr. 2000;130(23):889–895.
   PubMedGoogle Scholar
• de Souza Zago VH, Tanus-Santos JE, Gardin Danelon MR, et al. Chemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin. Int J Clin Pharmacol Ther. 2014;52(04):277–283. doi:10.5414/CP201742
   PubMed Web of Science ®Google Scholar
• Capurso A. Le promesse delle statine [The promise of statins]. Ital Heart J Suppl. 2000;2(3):224–229.
   Google Scholar
• Bargon J. Statine: stumpfes Schwert gegen COPD-Exazerbationen. MMW Fortschr Med. 2020;162(12):26–27. doi:10.1007/s15006-020-0604-7
   PubMedGoogle Scholar
• Lin CM, Yang TM, Yang YH, et al. Statin use and the risk of subsequent hospitalized exacerbations in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis. 2020;15:289–299. doi:10.2147/COPD.S229047
   PubMed Web of Science ®Google Scholar
• Narsingam S, Bozarth AL, Abdeljalil A. Updates in the management of stable chronic obstructive pulmonary disease. Postgrad Med. 2015;127(7):758–770. doi:10.1080/00325481.2015.1084212
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi:10.1056/NEJMoa1403086
   PubMed Web of Science ®Google Scholar
• Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med. 2013;126(7):598–606.e2. doi:10.1016/j.amjmed.2013.01.036
   PubMed Web of Science ®Google Scholar
• Huang CC, Chan WL, Chen YC, et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin Ther. 2011;33(10):1365–1370. doi:10.1016/j.clinthera.2011.08.010
   PubMed Web of Science ®Google Scholar
• Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62(9):1373–1378. doi:10.1111/j.1742-1241.2008.01731.x
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40. doi:10.1136/thoraxjnl-2014-205795
   PubMed Web of Science ®Google Scholar
• Johnson JD, Theurer WM. A stepwise approach to the interpretation of pulmonary function tests. Am Fam Physician. 2014;89(5):359–366.
   PubMed Web of Science ®Google Scholar
• Milne S, Jetmalani K, Chapman DG, et al. Respiratory system reactance reflects communicating lung volume in chronic obstructive pulmonary disease. J Appl Physiol. 2019;126(5):1223–1231. doi:10.1152/japplphysiol.00503.2018
   PubMed Web of Science ®Google Scholar
• Bernabeu-Mora R, Sánchez-Martínez MP, Montilla-Herrador J, et al. GOLD Stages of COPD: transitions, predictor factors and comparison with 2017 GOLD stages. Int J Chron Obstruct Pulmon Dis. 2011;2020(15):1519–1527.
   Google Scholar
• Soriano JB, Hahsler M, Soriano C, et al. CHAIN investigators. Temporal transitions in COPD severity stages within the GOLD 2017 classification system. Respir Med. 2018;142:81–85. doi:10.1016/j.rmed.2018.07.019
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD network registry. Int J Chron Obstruct Pulmon Dis. 2018;13:3947–3955. doi:10.2147/COPD.S182905
   PubMed Web of Science ®Google Scholar
• van Haarst A, McGarvey L, Paglialunga S. Review of drug development guidance to treat chronic obstructive pulmonary disease: US and EU perspectives. Clin Pharmacol Ther. 2019;106(6):1222–1235. doi:10.1002/cpt.1540
   PubMed Web of Science ®Google Scholar
• World Health Organisation. International statistical classification of diseases and related health problems. 10th revision, 5th ed, 2016; 2016. Available from: file:///C:/Users/J/AppData/Local/Temp/9789241549165-V1-eng-2.pdf. Accessed December 31, 2020.
   Google Scholar
• Leidy NK, Wilcox TK, Jones PW, et al. EXACT-PRO Study Group. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13(8):965–975. doi:10.1111/j.1524-4733.2010.00772.x
   PubMed Web of Science ®Google Scholar
• Gayle A, Dickinson S, Morris K, Poole C, Mathioudakis AG, Vestbo J. What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs. Int J Chron Obstruct Pulmon Dis. 2018;13:3485–3492. doi:10.2147/COPD.S173664
   PubMed Web of Science ®Google Scholar
• Yamakuchi M, Greer JJ, Cameron SJ, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res. 2005;96(11):1185–1192. doi:10.1161/01.RES.0000170229.49776.81
   PubMed Web of Science ®Google Scholar
• Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357–363. doi:10.1370/afm.983
   PubMed Web of Science ®Google Scholar
• Lowry R. Confidence Interval of a Proportion; 2020. Available from: http://vassarstats.net/prop1.html. Accessed December 31, 2020.
   Google Scholar
• Kummer J. Statistics Calculator. Calculator for producing statistics about a dataset. averages and other statistical measures; 2020. Available from: https://jumk.de/statistik-rechner/. Accessed December 31, 2020.
   Google Scholar
• Navendu Vasavada Statistics. Mann Whitney test for unpaired data, two sample; 2016. Available from: http://astatsa.com/WilcoxonTest/. Accessed December 31 2020.
   Google Scholar
• Lowry R. Contingency table—VassarStats; 2020. Available from: http://vassarstats.net/newcs.html. Accessed December 31, 2020.
   Google Scholar
• Huchon DJR. Calculator for survival probabilities (Kaplan-Meier Method). Available from: http://www.hutchon.net/Kaplan-Meier.htm. Accessed December 31, 2020.
   Google Scholar
• Neukamm A, Høiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med. 2015;278(1):59–67. doi:10.1111/joim.12337
   PubMed Web of Science ®Google Scholar
• Carlson AA, Smith EA, Reid DJ. The stats are in: an update on statin use in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2277–2284. doi:10.2147/COPD.S78875
   PubMed Web of Science ®Google Scholar
• Yayan J. No significant detectable anti-infection effects of aspirin and statins in chronic obstructive pulmonary disease. Int J Med Sci. 2015;12(3):280–287. doi:10.7150/ijms.11054
   PubMed Web of Science ®Google Scholar
• Thomson NC. Clinical studies of statins in asthma and COPD. Curr Mol Pharmacol. 2017;10(1):60–71. doi:10.2174/1874467209666160112125911
   PubMed Web of Science ®Google Scholar
• Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA normative aging study. Am J Respir Crit Care Med. 2007;176(8):742–747. doi:10.1164/rccm.200705-656OC
   PubMed Web of Science ®Google Scholar
• van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008;102(2):192–196. doi:10.1016/j.amjcard.2008.03.038
   PubMed Web of Science ®Google Scholar
• Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009;9(1):32. doi:10.1186/1471-2466-9-32
   PubMedGoogle Scholar
• Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008;101(4):530–535. doi:10.1016/j.amjcard.2007.09.102
   PubMed Web of Science ®Google Scholar
• Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006–1012. doi:10.1378/chest.06-1997
   PubMed Web of Science ®Google Scholar
• Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29(2):279–283. doi:10.1183/09031936.00106406
   PubMed Web of Science ®Google Scholar
• Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007;212(3):265–273. doi:10.1620/tjem.212.265
   PubMed Web of Science ®Google Scholar
• Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47(12):2554–2560. doi:10.1016/j.jacc.2006.04.039
   PubMed Web of Science ®Google Scholar
• Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest. 2007;132(6):1764–1771. doi:10.1378/chest.07-0298
   PubMed Web of Science ®Google Scholar